Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response
CardioVascular and Interventional Radiology · 2023
DOI: 10.1007/s00270-022-03346-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift CardioVascular and Interventional Radiology, 2023. Verfasst von Κ Malagari und 12 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: The study was supported by 'Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation, The study was supported by ‘Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.
Abstract (Originalsprache)
PURPOSE: The primary objectives of this study were to evaluate safety, and efficacy of Transarterial Chemoembolization (TACE) using doxorubicin-loaded radiopaque microspheres (DC Bead LUMI™) for the treatment of early and intermediate stage Hepatocellular Carcinoma (HCC) not amenable for curative treatments. Distribution of the microspheres was correlated with results post embolization. MATERIALS AND METHODS: This was a prospective, single arm, open label study. The primary outcome measures were distribution of the radiopaque microspheres as showed by computerized tomography (CT) and local response measured by modified Response Evaluation Criteria (mRECIST) after Magnetic Resonance Imaging (MRI). Secondary measures were Time to Progression (TTP) and Overall Survival (OS). RESULTS: Fifty patients were enrolled over 36 months. Median age was 69.0 years; mean sum of target lesions diameters was 78.6 ± 36.8 mm. There were no Grade 4 or 5 adverse events (AEs). At 6 months Complete Response (CR) (18%), Partial Response (PR) (62%), Objective Response OR (80%) and Stable Disease (SD) (20%) were recorded. Before embolization, Diffusion Weighted Imaging (DWI) showed high signal (restricted diffusion). Post procedure, patients with dense deposition (< 5 mm distance of microsphere aggregations) showed 100% absence of enhancement and no restriction in 30.6%. Median TTP was 8.3 months. TTP for patients with CR was 13.3 months and 7.2 and 5.6 for PR and SD, respectively. At 6 and 36 months, survival was 94% and 34%, respectively. CONCLUSION: DC Bead LUMI™ is well tolerated and effective in early and intermediate stage HCC with maximal necrosis obtained in dense deposition in the target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece. kmalag@otenet.gr.
- 2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
- Department of Tzanion, General Hospital Pireus, Pireus, Greece.
- Second Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Palliative Care, Agios Savvas Anticancer Hospital, Athens, Greece.
- University Hospital of Ioannina, Ioannina, Greece.
Förderung
- The study was supported by 'Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation
- The study was supported by ‘Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation
Zitieren
APA
Malagari, Κ., Kiakidis, T., Moschouris, H., Deutsch, M., Tanteles, S., Pantou, E., Panagiotou, I., Koskinas, J., Glantzounis, G. K., Alexopoulou, A., Filippiadis, D., Brountzos, E., & Kelekis, N. (2023). Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-022-03346-1
Vancouver
Malagari Κ, Kiakidis T, Moschouris H, Deutsch M, Tanteles S, Pantou E, et al. Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. CardioVascular and Interventional Radiology. 2023. doi:10.1007/s00270-022-03346-1
BibTeX
@article{Malagari2023,
author = {Malagari, Κ and Kiakidis, Th and Moschouris, Hip and Deutsch, M and Tanteles, S and Pantou, Eir and Panagiotou, I and Koskinas, J and Glantzounis, G K and Alexopoulou, A and Filippiadis, D and Brountzos, E and Kelekis, N},
title = {Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response},
journal = {CardioVascular and Interventional Radiology},
year = {2023},
doi = {10.1007/s00270-022-03346-1}
}
EUVIMED